Tags: Drug.

Radezolid (INN codenamed RX-1741) is a novel oxazolidinone antibiotic being developed by Rib-X Pharmaceuticals Inc. for the treatment of serious multi-drug–resistant infections. Radezolid has completed two phase-II clinical trials. One of these clinical trials was for uncomplicated skin and skin-structure infections (uSSSI) and the other clinical trial was for community acquired pneumonia (CAP).

Radezolid.svg
ATC prefix
none
CAS number
869884-78-6
FDA UNII code
53PC6LO35W
IUPAC name
N-[(5S)-3-(2-fluoro-4′-[(1H-123-triazol-5-ylmethyl)amino]methylbiphenyl-4-yl)-2-oxo-13-oxazolidin-5-yl]methylacetamide
PubChem
11224409

Loading...

This page contains content from the copyrighted Wikipedia article "Radezolid"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.